Synergy Pharmaceuticals Announces License Agreement with Luoxin Pharmaceutical Group. Yafo Capital Acted as The Exclusive Financial Advisor on This Transaction

August 8, 2018 - Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced yesterday that the company had entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin). Yafo Capital acted as the exclusive financial advisor on this transaction.

Under the terms of the agreement, Luoxin will have exclusive rights to develop and commercialize Synergy’s lead product TRULANCE® (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in mainland China, Hong Kong and Macau. Synergy will receive an upfront payment of $12 million. Synergy is also eligible, in the event that certain regulatory and commercial milestones are met, to receive additional payments of up to $56 million in aggregate. In addition, Synergy is eligible to receive tiered royalty payments on aggregate net sales. Luoxin will lead clinical development in China and be responsible for all activities and expenses relating to clinical development, regulatory approval, and commercialization in China.

"Luoxin is a leading pharmaceutical company in China with strong capabilities for successfully delivering TRULANCE to patients in its market," said Troy Hamilton, Chief Executive Officer of Synergy Pharmaceuticals Inc. " We look forward to supporting the Luoxin team in their efforts to bring TRULANCE to patients suffering from CIC and IBS-C in China.”

"We are pleased to partner with Synergy to bring this exciting new treatment option to benefit millions of patients suffering from these chronic gastrointestinal conditions in China." said Ryan Liu, Executive Chairman of Luoxin. “Over the years, Luoxin has established a strong product line of proton pump inhibitors to treat gastrointestinal diseases, and TRULANCE will make an invaluable addition to our arsenal of solutions to fight these conditions.”

"Yafo Capital showed deep industry understanding and very professional in this transaction. While being able to consider mutual interests for both parties, the team could provide and implement comprehensive solutions advising in the deal." Synergy's Chief Strategic Officer, Marino Garcia said.

"Yafo Capital has emphasized on oversea innovative drugs in gastroenterology, oncology, and cardiovascular sectors. Over the past several years, we have contacted many related companies in Europe and the U.S., helping these companies explore the Chinese market. Meanwhile, we also help Chinese companies search for innovative assets in foreign markets", Kun Tao (Managing Partner) and Fan Zheng (Managing Director) of Yafo Capital both involved in sourcing and negotiation of the deal, “We are very pleased to introduce Synergy’s Trulance to China. Under the strong research capability and nationwide distribution channels of Luoxin Pharma, we believe the product will be on the market soon, providing a better solution for constipation patients.”

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. Synergy’s proprietary GI platform includes one commercial product TRULANCE® (plecanatide) and a second product candidate – dolcanatide.

About Luoxin

Luoxin Pharmaceutical is a pharmaceutical company in China that engages in pharmaceutical research and development, manufacture, sales, and healthcare services with 6,500+ employees and sales reaching 1.4 billion US dollars. The company provides pharmaceutical products in gastrointestinal, respiratory, cardiovascular, infectious diseases and cancer, among other therapeutic areas.

About Yafo Capital

Shanghai Yafo Capital, as a boutique fund management and investment banking firm, specializes in cross-border private equity and M&A transactions. We are headquartered in Shanghai, with offices in Israel and the US. Yafo Life Science is the healthcare arm under Yafo Capital, with a focus on global pharmaceutical and medical device companies that have a ‘China Angle’. We are dedicated to bridge the global medical technologies and China market and capital.


美国Synergy Pharmaceuticals制药企业与山东罗欣药业签订许可协议。雅法资本担任独家财务顾问

2018年8月7日,美国医药上市公司Synergy Pharmaceuticals Inc. (股票代码SGYP,以下简称“Synergy”)宣布与山东罗欣药业集团股份有限公司(以下简称“罗欣药业”)签订《License Agreement》(以下简称“许可协议”)。雅法资本在本次交易中担任独家财务顾问。

根据协议许可,罗欣药业将获得在中国大陆、香港、澳门独家开发及商业化Synergy产品TRULANCE®(普卡那肽)用于治疗成人慢性特发性便秘(CIC)和肠易激综合征(IBS-C)的权益。罗欣药业应根据协议约定向Synergy支付1200万美金许可费用。除此之外, Synergy也有资格获得额外的与监管和商业化挂钩的里程碑付款预计5600万美金及净销售收入分成。罗欣药业将负责统筹TRULANCE在中国的临床试验、注册审批、市场推广的活动及产生的相关费用。

"罗欣药业是中国领先的制药公司,具备在中国成功推广TRULANCE的能力",Synergy Pharmaceuticals首席执行官Troy Hamilton表示,“我们将会尽全力支持罗欣团队为中国CIC和IBS-C患者提供TRULANCE解决方案。“

"中国有数百万患者受到便秘的困扰,我们很高兴与Synergy合作,为这些患者带来新的解决方案,提高他们的生活质量",罗欣药业执行董事长刘振腾表示,“多年来,罗欣在消化道领域已经建立了强大、丰富的产品线,TRULANCE的加入将进一步强化我们在该领域的领头地位。罗欣坚持‘ 传递健康’的企业使命,我们期待与Synergy合作,共同为使更多患者可受益于TRULANCE而努力”

"雅法资本在本次的合作中表现出对行业的深度理解和专业水平。在平衡考虑双方利益的同时,能够提供完善的问题解决方案并得以实行",Synergy的首席策略官Marino Garcia表示。

"雅法资本致力于向国内引进肿瘤、心脑血管、消化道等领域的海外创新药。在过去的几年中,我们接触了大量相关领域的药和器械项目。在帮助国外产品进驻中国的同时,我们也为国内企业主动寻找和接触这些领域的海外公司。"雅法资本管理合伙人陶锟与董事总经理郑帆全程参与了项目的引进与谈判, “我们很高兴能将Synergy公司的新药Trulance引进中国,罗欣药业在消化系统领域拥有很强的研发和销售能力,我们希望该产品能尽快在国内上市,为国内便秘患者提供更好的解决方案。”

关于Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc是一家生物制药公司,是纳斯达克上市公司。公司专注于创新消化道(GI)疗法的开发和商业化。公司围绕尿鸟苷蛋白(一种天然人体胃肠肽)的类似物,开发用于治疗胃肠疾病的创新药。 Synergy的专有消化道治疗平台包括一款已经商业化的产品TRULANCE®(普卡那肽)和另外一款候选产品 —dolcanatide。

关于山东罗欣药业集团股份有限公司

山东罗欣药业集团股份有限公司是集药品研发、生产、贸易及医疗健康服务为一体的中国制药工业百强企业。罗欣成立于1988年,现已发展成为拥有员工超过6500人,销售额达14亿美元的公司。公司产品覆盖消化道,呼吸系统,心血管疾病,传染病和癌症等多个治疗领域。

关于雅法资本

上海雅法资本作为新型投资和金融服务机构,致力于海外高科技项目的投资、融资、海外并购,总部位于上海,在北京、佛山、以色列及美国均设有分支机构。雅法生命科学(Yafo Life Science)是雅法资本旗下的医疗大健康部门,专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作;为中国医疗企业提供海外市场研究服务,寻找海外投资、并购标的,及药品和器械的商业合作。雅法生命科学致力于成为全球医疗技术对接中国市场与资本的桥梁。目前覆盖以色列、美国、瑞士、日本等八个医疗创新能力最强的国家。